secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001516551-24-000059
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience Phase 2a trial of SBI-100 OE fails primary endpoint; discontinues ophthalmology program
--------------------------------------------------------------------------------

- Phase 2a trial of SBI-100 in 56 patients with POAG or OHT did not meet primary IOP endpoint vs placebo.
- Drug safe; all patients completed study with no early discontinuations due to adverse events.
- Company discontinues all SBI-100 development and ophthalmology pipeline; focuses on obesity program with Nimacimab.
- Phase 2 obesity trial of Nimacimab expected to start Q3 2024; cash runway extended into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000059/0001516551-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000059/skye-20240610.htm
  HTML page:      https://secwatch.observer/filing/0001516551-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer